Canadian Cancer Trials Group

This study is testing whether a new targeted radiation drug called 177Lu-PSMA-617 can slow the growth of advanced prostate cancer better than the standard chemotherapy drug, docetaxel. It is for men whose cancer has spread and is no longer responding to standard hormone-blocking …

This study is testing whether adding a drug called durvalumab after standard bladder cancer treatment helps patients stay cancer-free longer. Durvalumab is an immunotherapy that helps the body's own immune system find and fight cancer cells. The trial will enroll 82 patients who …

This study is testing new combinations of cancer drugs to see if they work better than the current standard treatment for aggressive B-cell lymphoma that has come back or stopped responding to initial therapy. About 129 patients will be randomly assigned to receive either a new d…

This study is testing whether a drug called palbociclib can help control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It involves 19 men whose cancer has progressed despite previous therapies. Researchers will monitor how the can…

This study is testing if adding targeted radiation or surgery to destroy a few cancer spots improves outcomes for men whose prostate cancer has spread. It compares standard hormone-blocking drugs alone to those drugs plus this 'ablative therapy' to all visible cancer sites. The g…

This study is testing whether doctors can safely give less radiation to certain lymph node areas in patients with a specific type of throat cancer linked to HPV. The goal is to reduce treatment side effects like trouble swallowing and dry mouth without increasing the risk of the …

This study is testing a new oral drug, CFI-402257, given alongside a standard weekly chemotherapy (paclitaxel) for people with advanced HER2-negative breast cancer. The first part aims to find the safest dose of the new drug combination. The second part will see if adding this ne…

This study is testing whether adding a new drug called ipatasertib to standard fulvestrant therapy can better control advanced breast cancer that has started growing again after initial treatment. It involves about 250 postmenopausal women whose cancer is hormone-sensitive and HE…

This study is testing whether immunotherapy drugs can work as well as or better than standard chemotherapy when combined with radiation to treat a type of throat cancer linked to HPV. It will compare the standard treatment (radiation plus cisplatin chemotherapy) against two appro…

This study is testing whether combining two new drugs can help control advanced triple-negative breast cancer. The trial involves 15 women whose cancer has spread or cannot be removed by surgery. Researchers want to see if the drug combination can shrink tumors and slow cancer gr…

This study is testing whether a structured physical activity program can help prevent colon cancer from coming back in people who have already had surgery and chemotherapy. It will compare a group that gets the exercise program plus health education to a group that gets health ed…

This study is testing a new treatment for advanced solid tumors that have spread and are incurable. It uses two specially engineered viruses designed to kill cancer cells and train the immune system to attack the tumor. The main goals are to find the safest and most effective dos…

This study is testing a new oral drug called CFI-400945 for women with advanced breast cancer that has spread and stopped responding to standard chemotherapy. The drug works by blocking a specific protein that helps cancer cells grow and divide. The main goal is to see if the dru…

This study is testing whether new drug treatments given before surgery can shrink lung tumors and prevent cancer from coming back. It's for people with early-stage non-small cell lung cancer that can be surgically removed. Researchers are looking at how patients' specific cancer …

This study is testing whether daily low-dose aspirin can help prevent ovarian cancer in women who carry high-risk BRCA gene mutations. Participants are women already scheduled for preventive ovary removal surgery. They take either aspirin or a placebo pill daily for up to two yea…